455 related articles for article (PubMed ID: 14979736)
1. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
Nicholas JC
Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
[TBL] [Abstract][Full Text] [Related]
2. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
3. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
Dunn CJ; Wagstaff AJ
Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
5. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
6. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
7. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
8. Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.
Soffritti S; Russo G; Cantelli S; Gilli G; Catizone L
BMC Nephrol; 2009 Oct; 10():33. PubMed ID: 19852833
[TBL] [Abstract][Full Text] [Related]
9. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
Walker R; Pussell BA;
Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
[TBL] [Abstract][Full Text] [Related]
10. UK Renal Registry 11th Annual Report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses.
Richardson D; Ford D; Gilg J; Williams AJ
Nephron Clin Pract; 2009; 111 Suppl 1():c149-83. PubMed ID: 19542697
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.
Krivoshiev S; Todorov VV; Manitius J; Czekalski S; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 May; 24(5):1407-15. PubMed ID: 18394266
[TBL] [Abstract][Full Text] [Related]
12. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.
Furuland H; Linde T; Ahlmén J; Christensson A; Strömbom U; Danielson BG
Nephrol Dial Transplant; 2003 Feb; 18(2):353-61. PubMed ID: 12543892
[TBL] [Abstract][Full Text] [Related]
14. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
Webb L; Gilg J; Wilkie M
Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
[TBL] [Abstract][Full Text] [Related]
15. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
16. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
17. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
Levin NW; Fishbane S; Cañedo FV; Zeig S; Nassar GM; Moran JE; Villa G; Beyer U; Oguey D;
Lancet; 2007 Oct; 370(9596):1415-21. PubMed ID: 17950856
[TBL] [Abstract][Full Text] [Related]
18. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
19. [Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa].
Remón C; Quirós P; Fernández Marchena D; Hernández Romero M; del Castillo R; Fernández Ruiz E
Nefrologia; 2005; 25(2):170-7. PubMed ID: 15912654
[TBL] [Abstract][Full Text] [Related]
20. Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study.
Frei U; Kwan JT; Spinowitz BS;
BMC Nephrol; 2009 Feb; 10():5. PubMed ID: 19243619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]